<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02426632</url>
  </required_header>
  <id_info>
    <org_study_id>CR106726</org_study_id>
    <secondary_id>53718678RSV1003</secondary_id>
    <secondary_id>2014-005157-39</secondary_id>
    <nct_id>NCT02426632</nct_id>
  </id_info>
  <brief_title>Study to Evaluate Taste Profile of Different JNJ-53718678 Oral Liquid Formulations in Healthy Participants</brief_title>
  <official_title>A Phase 1, Double-blind, Randomized, Trial to Evaluate the Taste Profile of Different JNJ-53718678 Oral Liquid Formulations in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Janssen Sciences Ireland UC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Janssen Sciences Ireland UC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective is to evaluate in a double-blinded (neither physician nor participant
      knows the treatment that the participant receives), fashion the taste of different
      JNJ-53718678 oral liquid formulations as compared to the reference formulation (JNJ-53718678,
      10 milligram/milliliter oral solution without sweetener/flavor).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 1, double-blind, randomized (participants taste the same groups of drugs
      [formulations] but in random order), single-center trial in healthy adult participants. The
      study will include 2 Sessions of 1 day, 1) Session 1, in which participants will receive 6
      JNJ-53718678 oral solutions (1 reference and 5 different formulations) sequentially in a
      randomized order, Scoring of the taste will be done via a questionnaire designed for this
      purpose; 2) Session 2, within approximately a timeframe of 7 to 14 days after completion of
      Session 1, participants will taste 2 best scoring tastes coming out of Session 1. The study
      will consist of a screening phase of approximately 2 weeks, treatment phase of approximately
      2 weeks and a post-treatment follow-up phase of 10 days after completion of the last Session.
      The total study duration for each participant will be approximately 6 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 4, 2015</start_date>
  <completion_date type="Actual">April 24, 2015</completion_date>
  <primary_completion_date type="Actual">April 24, 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Acceptability Score</measure>
    <time_frame>up to 12 hour post-administration of study drug</time_frame>
    <description>Formulations will be assessed using Acceptability Questionnaire, which evaluates sweetness, bitterness, aroma type, aroma strength, smell and overall acceptability using visual analogue scales (VAS) with range from 0 (super bad) to 100 (super good).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Local and Systemic adverse Events</measure>
    <time_frame>Screening up to end of Study (Week 6)</time_frame>
  </secondary_outcome>
  <number_of_arms>12</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Session 1: Sequence 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will sequentially receive 5 milliliter of each 6 JNJ-53718678 formulations (ABCDEF) in a random order, at a dosing interval of 1-2 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Session 1: Sequence 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will sequentially receive 5 milliliter of each 6 JNJ-53718678 formulations (ABCDEF) in a random order, at a dosing interval of 1-2 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Session 1: Sequence 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will sequentially receive 5 milliliter of each 6 JNJ-53718678 formulations (ABCDEF) in a random order, at a dosing interval of 1-2 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Session 1: Sequence 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will sequentially receive 5 milliliter of each 6 JNJ-53718678 formulations (ABCDEF) in a random order, at a dosing interval of 1-2 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Session 1: Sequence 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will sequentially receive 5 milliliter of each 6 JNJ-53718678 formulations (ABCDEF) in a random order, at a dosing interval of 1-2 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Session 1: Sequence 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will sequentially receive 5 milliliter of each 6 JNJ-53718678 formulations (ABCDEF) in a random order, at a dosing interval of 1-2 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Session 2: Sequence 7</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive two best scoring formulations from Session 1 with a varying concentration of sucralose (M1M2M3N1N2N3) sequentially in a random order, at a dosing interval of 1-2 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Session 2: Sequence 8</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive two best scoring formulations from Session 1 with a varying concentration of sucralose (M1M2M3N1N2N3) sequentially in a random order, at a dosing interval of 1-2 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Session 2: Sequence 9</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive two best scoring formulations from Session 1 with a varying concentration of sucralose (M1M2M3N1N2N3) sequentially in a random order, at a dosing interval of 1-2 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Session 2: Sequence 10</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive two best scoring formulations from Session 1 with a varying concentration of sucralose (M1M2M3N1N2N3) sequentially in a random order, at a dosing interval of 1-2 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Session 2: Sequence 11</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive two best scoring formulations from Session 1 with a varying concentration of sucralose (M1M2M3N1N2N3) sequentially in a random order, at a dosing interval of 1-2 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Session 2: Sequence 12</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive two best scoring formulations from Session 1 with a varying concentration of sucralose (M1M2M3N1N2N3) sequentially in a random order, at a dosing interval of 1-2 hours.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Formulation A</intervention_name>
    <description>Reference formulation, 10 milligram/milliliter (mg/mL)oral solution without sweetener/flavor.</description>
    <arm_group_label>Session 1: Sequence 1</arm_group_label>
    <arm_group_label>Session 1: Sequence 2</arm_group_label>
    <arm_group_label>Session 1: Sequence 3</arm_group_label>
    <arm_group_label>Session 1: Sequence 4</arm_group_label>
    <arm_group_label>Session 1: Sequence 5</arm_group_label>
    <arm_group_label>Session 1: Sequence 6</arm_group_label>
    <other_name>JNJ-53718678</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Formulation B</intervention_name>
    <description>10 mg/mL oral solution containing 2 mg/mL sucralose, masking flavor and orange flavor.</description>
    <arm_group_label>Session 1: Sequence 1</arm_group_label>
    <arm_group_label>Session 1: Sequence 2</arm_group_label>
    <arm_group_label>Session 1: Sequence 3</arm_group_label>
    <arm_group_label>Session 1: Sequence 4</arm_group_label>
    <arm_group_label>Session 1: Sequence 5</arm_group_label>
    <arm_group_label>Session 1: Sequence 6</arm_group_label>
    <other_name>JNJ-53718678</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Formulation C</intervention_name>
    <description>10 mg/mL oral solution containing 10 mg/mL sucralose.</description>
    <arm_group_label>Session 1: Sequence 1</arm_group_label>
    <arm_group_label>Session 1: Sequence 2</arm_group_label>
    <arm_group_label>Session 1: Sequence 3</arm_group_label>
    <arm_group_label>Session 1: Sequence 4</arm_group_label>
    <arm_group_label>Session 1: Sequence 5</arm_group_label>
    <arm_group_label>Session 1: Sequence 6</arm_group_label>
    <other_name>JNJ-53718678</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Formulation D</intervention_name>
    <description>10 mg/mL oral solution containing 2 mg/mL sucralose and raspberry flavor.</description>
    <arm_group_label>Session 1: Sequence 1</arm_group_label>
    <arm_group_label>Session 1: Sequence 2</arm_group_label>
    <arm_group_label>Session 1: Sequence 3</arm_group_label>
    <arm_group_label>Session 1: Sequence 4</arm_group_label>
    <arm_group_label>Session 1: Sequence 5</arm_group_label>
    <arm_group_label>Session 1: Sequence 6</arm_group_label>
    <other_name>JNJ-53718678</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Formulation E</intervention_name>
    <description>10 mg/mL oral solution containing 2 mg/mL sucralose and strawberry flavor.</description>
    <arm_group_label>Session 1: Sequence 1</arm_group_label>
    <arm_group_label>Session 1: Sequence 2</arm_group_label>
    <arm_group_label>Session 1: Sequence 3</arm_group_label>
    <arm_group_label>Session 1: Sequence 4</arm_group_label>
    <arm_group_label>Session 1: Sequence 5</arm_group_label>
    <arm_group_label>Session 1: Sequence 6</arm_group_label>
    <other_name>JNJ-53718678</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Formulation F</intervention_name>
    <description>10 mg/mL oral solution containing 2 mg/mL sucralose and orange flavor.</description>
    <arm_group_label>Session 1: Sequence 1</arm_group_label>
    <arm_group_label>Session 1: Sequence 2</arm_group_label>
    <arm_group_label>Session 1: Sequence 3</arm_group_label>
    <arm_group_label>Session 1: Sequence 4</arm_group_label>
    <arm_group_label>Session 1: Sequence 5</arm_group_label>
    <arm_group_label>Session 1: Sequence 6</arm_group_label>
    <other_name>JNJ-53718678</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Formulation M1</intervention_name>
    <description>Best scoring formulation from Session 1 with a varying concentration of sucralose (maximum 10 mg/mL).</description>
    <arm_group_label>Session 2: Sequence 7</arm_group_label>
    <arm_group_label>Session 2: Sequence 8</arm_group_label>
    <arm_group_label>Session 2: Sequence 9</arm_group_label>
    <arm_group_label>Session 2: Sequence 10</arm_group_label>
    <arm_group_label>Session 2: Sequence 11</arm_group_label>
    <arm_group_label>Session 2: Sequence 12</arm_group_label>
    <other_name>JNJ-53718678</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Formulation M2</intervention_name>
    <description>Best scoring formulation from Session 1 with a varying concentration of sucralose (maximum 10 mg/mL).</description>
    <arm_group_label>Session 2: Sequence 7</arm_group_label>
    <arm_group_label>Session 2: Sequence 8</arm_group_label>
    <arm_group_label>Session 2: Sequence 9</arm_group_label>
    <arm_group_label>Session 2: Sequence 10</arm_group_label>
    <arm_group_label>Session 2: Sequence 11</arm_group_label>
    <arm_group_label>Session 2: Sequence 12</arm_group_label>
    <other_name>JNJ-53718678</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Formulation M3</intervention_name>
    <description>Best scoring formulation from Session 1 with a varying concentration of sucralose (maximum 10 mg/mL).</description>
    <arm_group_label>Session 2: Sequence 7</arm_group_label>
    <arm_group_label>Session 2: Sequence 8</arm_group_label>
    <arm_group_label>Session 2: Sequence 9</arm_group_label>
    <arm_group_label>Session 2: Sequence 10</arm_group_label>
    <arm_group_label>Session 2: Sequence 11</arm_group_label>
    <arm_group_label>Session 2: Sequence 12</arm_group_label>
    <other_name>JNJ-53718678</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Formulation N1</intervention_name>
    <description>Second best scoring formulation from Session 1 with a varying concentration of sucralose (maximum 10 mg/mL).</description>
    <arm_group_label>Session 2: Sequence 7</arm_group_label>
    <arm_group_label>Session 2: Sequence 8</arm_group_label>
    <arm_group_label>Session 2: Sequence 9</arm_group_label>
    <arm_group_label>Session 2: Sequence 10</arm_group_label>
    <arm_group_label>Session 2: Sequence 11</arm_group_label>
    <arm_group_label>Session 2: Sequence 12</arm_group_label>
    <other_name>JNJ-53718678</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Formulation N2</intervention_name>
    <description>Second best scoring formulation from Session 1 with a varying concentration of sucralose (maximum 10 mg/mL).</description>
    <arm_group_label>Session 2: Sequence 7</arm_group_label>
    <arm_group_label>Session 2: Sequence 8</arm_group_label>
    <arm_group_label>Session 2: Sequence 9</arm_group_label>
    <arm_group_label>Session 2: Sequence 10</arm_group_label>
    <arm_group_label>Session 2: Sequence 11</arm_group_label>
    <arm_group_label>Session 2: Sequence 12</arm_group_label>
    <other_name>JNJ-53718678</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Formulation N3</intervention_name>
    <description>Second best scoring formulation from Session 1 with a varying concentration of sucralose (maximum 10 mg/mL).</description>
    <arm_group_label>Session 2: Sequence 7</arm_group_label>
    <arm_group_label>Session 2: Sequence 8</arm_group_label>
    <arm_group_label>Session 2: Sequence 9</arm_group_label>
    <arm_group_label>Session 2: Sequence 10</arm_group_label>
    <arm_group_label>Session 2: Sequence 11</arm_group_label>
    <arm_group_label>Session 2: Sequence 12</arm_group_label>
    <other_name>JNJ-53718678</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female participants of childbearing potential should have a urine pregnancy test at
             screening which should be negative

          -  Participants must be non-smokers and/or have not used chewing tobacco for at least one
             month prior to screening

          -  Participants must be willing/able to adhere to the prohibitions and restrictions
             specified in the protocol and study procedures

          -  Participants must be able to taste and smell normally, to their own opinion, at all
             times throughout the study duration. Participants who have an impaired sense of taste
             and/or smell due to any conditions like common cold or sinusitis are not eligible to
             take part or to continue to study

          -  Participants must agree to use an adequate method of contraception

        Exclusion Criteria:

          -  Participant has a mouth pathology including, but not limited to, pain, ulcer, edema,
             mucosal erosion, and/or (dental) abscesses, or receives treatment for oral pathologies
             or oral treatment for any disease

          -  Participant has a history of any illness that, in the opinion of the Investigator,
             might confound the results of the study or pose an additional risk in administering
             study drug to the participant or that could prevent, limit or confound the protocol
             specified assessments. This may include but is not limited to renal dysfunction,
             significant cardiac, vascular, pulmonary, gastrointestinal (such as significant
             diarrhea, gastric stasis, or constipation that in the Investigator's opinion could
             influence drug absorption or bioavailability), endocrine, neurologic, hematologic,
             rheumatologic, psychiatric, neoplastic, or metabolic disturbances

          -  Participants with a history of clinically significant allergies, hypersensitivity, or
             intolerance to drugs such as, but not limited to, sulfonamides and penicillins, drug
             allergy witnessed in previous studies with experimental drugs, or to JNJ-53718678 or
             its excipients

          -  Participants with a history or evidence of use of alcohol, barbiturates, amphetamines,
             recreational or narcotic drug use within the past 3 months, which in the
             Investigator's opinion would compromise participant's safety and/or compliance with
             the study procedures

          -  Participants having received an investigational drug (including investigational
             vaccines) or used an invasive investigational device within 3 months before the
             planned first dose of study drugs or is currently enrolled in an investigational study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janssen Sciences Ireland UC Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Janssen Sciences Ireland UC</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Nottingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 22, 2015</study_first_submitted>
  <study_first_submitted_qc>April 22, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 27, 2015</study_first_posted>
  <last_update_submitted>May 9, 2018</last_update_submitted>
  <last_update_submitted_qc>May 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Healthy</keyword>
  <keyword>JNJ-53718678</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

